(2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

Tuesday, October 28, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
Abstract Poster Presenter: Thomas Grader-Beck, MD – Johns Hopkins
10:30 AM - 12:30 PM Central Time

Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren's Disease
Abstract Poster Presenter: Alejandro Gómez Gómez, PhD – Hospital Universitari Vall d'Hebron
10:30 AM - 12:30 PM Central Time

Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
Abstract Poster Presenter: Divi Cornec, MD PhD (he/him/his) – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
10:30 AM - 12:30 PM Central Time

Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
Abstract Poster Presenter: sandrine jousse joulin, MD – cavale blanche hospital
10:30 AM - 12:30 PM Central Time

Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Abstract Poster Presenter: Alejandro Gómez Gómez, PhD – Hospital Universitari Vall d'Hebron
10:30 AM - 12:30 PM Central Time

Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren's Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Abstract Poster Presenter: Ana Medeiros-Ribeiro, MD, PhD (she/her/hers) – Hospital das Clinicas da Faculdade de Medicina da USP
10:30 AM - 12:30 PM Central Time

Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Abstract Poster Presenter: Deepak Rath, MD, MBBS, DM – John H Stroger Hospital Jr of Cook County, Chicago, Illinois 60612
10:30 AM - 12:30 PM Central Time

Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome
Abstract Poster Presenter: Carlota Navarro Joven, -None- – Hospital Universitario de Fuenlabrada
10:30 AM - 12:30 PM Central Time

Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Abstract Poster Presenter: Sara Stern, MD – University of Utah
10:30 AM - 12:30 PM Central Time

Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
Abstract Poster Presenter: Faye Yu, BSc – Johnson & Johnson Innovative Medicine
10:30 AM - 12:30 PM Central Time

Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
Abstract Poster Presenter: Yuebo Jin, MD – Peking University People's Hospital
10:30 AM - 12:30 PM Central Time

When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
Abstract Poster Presenter: Kyung Ann Lee, MD, PhD (she/her/hers) – Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital
10:30 AM - 12:30 PM Central Time

Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Abstract Poster Presenter: Paula Valentina Estrada Alarcón, MD, PhD – H Moisès Broggi
10:30 AM - 12:30 PM Central Time

CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Abstract Poster Presenter: Antoine Sreih, MD – Cullinan Therapeutics
10:30 AM - 12:30 PM Central Time

Updates in the local treatments in Primary Sjögren's Syndrome “Efficacy and Safety”
Abstract Poster Presenter: Marta Ramírez Martín, MD (she/her/hers) – Hospital University Principe de Asturias